Sub(acute) Neuropsychopharmacological Profiling of 2C-B Versus Psilocybin

Maastricht University0 sites18 target enrollmentTBD

Overview

No summary available.

Registry

who.int

Start Date

TBD

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Sponsor

•1\. Previous experience with at least one psychedelic substance (e.g., psilocybin, LSD, DMT,
•ayahuasca, psilocybe fungi \=1 times) but not within the past three months.
•2\. Aged between 18 and 40 years.
•3\. Free from medication (any drug prescribed for a medical indication).
•4\. The participant is, in the opinion of the investigator, generally healthy based on assessment of
•medical history, physical examination, vital signs, electrocardiogram (ECG), and the results of the
•haematology, clinical chemistry, urinalysis, serology, and other laboratory tests.
•5\. A resting pulse and heart rate (as read on the ECG) \=51 bpm and \=100 bpm. For participants in
•good physical condition, the lower limit is \=45 bpm.
•6\. A resting systolic blood pressure \=91 mmHg and \=140 mmHg and a resting diastolic blood

•1\. Previous experience of serious side effects to psychedelic drugs (anxiety or panic attacks).
•2\. Use of medication (other than paracetamol).
•3\. History of drug addiction (determined by the medical questionnaire, drug questionnaire and
•medical examination).
•4\. Excessive alcohol consumption (\>20 units a week).
•5\. Excessive smoking (\>20 cigarettes a week).
•6\. Current or history of psychiatric disorder (determined by the medical questionnaire and
•medical examination).
•7\. Hypertension (diastolic \>90 mmHg; systolic \>140 mmHg).
•8\. Liver dysfunction (hepatitis, cirrhosis, cancer, biliary cholangitis, hemochromatosis, alcoholic